Our people

our strength is
our people

Since the creation of MedinCell, the know-how and the strong involvement of our collaborators have been essential elements of our development. In order to share our success and preserve our common ambition and the extra-financial mission of MedinCell, “to impact health positively”, all our employees become shareholders soon after their arrival. The desire to involve them from the start with our success has allowed the development of an entrepreneurial culture at all levels of the company.

148
people

30
nationalities

Our people

Our values

Power of the group
Challenge allows us to achieve better output and more robust decisions/actions

Purposeful Innovation
Our mission is to make drugs that treat patients

Trust
We trust each other

Respect
We act, interact and talk with the consideration we’d like others to have with us

Directness & transparency
We have the courage to share our thoughts, on a one to one basis

Adaptability
We accept uncertainty and are ready to adapt

Go beyond
We take ownership of issues we face

Fun
We want to have pleasure doing our job

Our people

Governance
Supervisory board

Philippe Guy

ESG committee president

During his 31 years with the Boston Consulting Group, Philippe advised several international companies in the pharmacy, biotechnology and medical device sectors in several areas, including Corporate Strategy and Business Units, Research and Development, Marketing and Manufacturing as well as Large-Scale Transformation and Integration following mergers/acquisitions. Previously, Philippe Guy was Global Head of Health Practice at BCG from 1997 to 2006. As a member of the Executive Committee of BCG, he was responsible for all BCG’s practices from 2003-2006. Philippe Guy is a graduate of the prestigious HEC (Hautes Etudes Commerciales) business school.

Elisabeth Kogan

Member of the Board

Co-founder and CEO of Clexio Biosciences, a clinical-stage pharmaceutical company developing novel drugs for neurological and psychiatric conditions, Elisabeth Kogan has over 20 years’ experience in the Pharmaceutical industry where she has held senior executive leadership roles with management responsibilities in R&D and sales & marketing. She has extensive experience of delivering innovation and new technology introduction from concept to implementation.

Tone Kvåle

Audit committee president

Tone Kvåle is the CFO of Herantis Pharma, and she has more than 25 years of experience from the biotech and life sciences industry. She was CFO at Nordic Nanovector, a publicly listed company in Norway, for 7 years, and prior to that, she held CFO roles at NorDiag (publicly listed company), Kavli Holding, Dynal Biotech, as well as senior management positions at Invitrogen/Life Technologies, in US, now part of Thermo Fisher. In these roles, she helped raise over EUR 200m in financing, was involved in IPO’s and M&A’s and was responsible for financial reporting under various reporting standards including US GAAP and IFRS. She has been board director and chair of the audit committee of Bonesupport AB (BONEX), Sweden from December 2016 until May 2022. Tone has a diploma in finance and administration from UiT, The Arctic University of Norway, Harstad. She has completed the prescribed course of study and the examination for Advanced Programme in Corporate Finance at The Norwegian School of Economics, NHH in 2022.

Virginie Lleu

Remuneration committee president

The Founder and Chief Executive Officer of L3S, one of Europe’s leading life sciences research firms, Virginie Lleu held a variety of health recruitment positions before setting up her first recruitment firm specializing in healthcare in 2003, which was sold to Whitehead Mann five years later. Virginie Lleu is also a member of two Boards of Directors: La Fondation Fondamentale (foundation for scientific cooperation dedicated to combating major psychiatric disorders) and LNC (a start-up specializing in the treatment of chronic metabolic diseases, specifically pre-diabetes and obesity). With a background is in clinical psychology (graduate degree), she began her career as a neuropsychologist in leading university hospitals in Paris. Virginie Lleu is a graduate in clinical psychology and pathology (DESS).

Sabri Markabi

Vice-president

A specialist in neuroscience and a graduate in pharmacology, Dr Sabri Markabi has spent more than twenty-five years in international positions in the pharmaceutical industry. In particular, he led the clinical neuroscience department and supervised the development of the ophthalmology unit at Novartis before heading up R&D at the Alcon pharmaceutical company from 2008 to 2015. During his career, Sabri Markabi has taken part in or chaired many corporate governance bodies in private or listed companies. Since 2015, he has advised many companies, specifically regarding their investment strategy and R&D.

Anh Nguyen

President

Dr Anh Nguyen, co-founder and Chairman of the Company’s Supervisory Board, is an experienced biotechnology entrepreneur. He co-founded Syntro, first listed on NASDAQ in 1987, and Invitrogen, first listed on NASDAQ in 1999, which later became Life Technologies and was acquired by ThermoFisher in 2013 for US$16 billion. Anh Nguyen is a molecular biologist with a PhD from the University of California at San Diego, and also completed the MBA program at the MIT Sloan School of Management.

Our people

Governance
Management

Julie
Alimi

Head of Legal

Jaime
Arango

Chief Financial Officer

Christophe
Douat

CEO

Quiterie de Beauregard

Head of Portfolio

Sébastien
Enault

Chief Business Officer

David
Heuzé

Head of Communications / IR

Adolfo Lopez-Noriega

Head of Research

Helen
Martin

Head of Alliance Management

Richard
Malamut

Chief Medical Officer

Franck
Pouzache

Chief People officer

Session en français

Rendez-vous le lundi 14 novembre à 18h00 (CET) pour une vidéoconférence dédiée aux récentes avancées des produits de notre portfeuille clinique

English session

On Monday 14, November at 6.00 pm (CET) participate in our videoconference dedicated to the latest news regarding our clinical and regulatory products

Êtes-vous un actionnaire de MedinCell ? / Are you a MedinCell shareholder?
Vous êtes / You are :
This field is for validation purposes and should be left unchanged.

CONTACT

  • This field is for validation purposes and should be left unchanged.